Flavii Therapeutics develops epigenetic therapies for central nervous system disorders with high unmet medical need.
Flavii Therapeutics has raised $945K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2026.
Flavii Therapeutics's investors include ICF Capital, Grow Venture Partners, WA4STEAM.
Flavii Therapeutics is headquartered in Barcelona, Spain.
Flavii Therapeutics develops epigenetic therapies for central nervous system disorders with high unmet medical need.
Flavii Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Flavii Therapeutics — Funding & Investors." VCBacked, October 9, 2026, https://www.vcbacked.co/company/flavii-therapeutics. Accessed November 5, 2026.
VCBacked. (2026). Flavii Therapeutics — Funding & Investors. Retrieved November 5, 2026, from https://www.vcbacked.co/company/flavii-therapeutics
{{cite web |title=Flavii Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flavii-therapeutics |website=VCBacked |access-date=November 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Flavii Therapeutics? Request a listing update